Pharma Co. Beats Investor Suit Over Wrinkle Drug Approval

By Sydney Price · April 1, 2024, 9:53 PM EDT

A California federal judge has dismissed a lawsuit from the investors of Revance Therapeutics Inc. accusing it and several executives of concealing quality control concerns that eventually led the U.S. Food...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

Aramic LLC v. Revance Therapeutics, Inc. et al

Case Number

Court

California Northern

Nature of Suit

Securities/Commodities

Date Filed

December 10, 2021

Recent Articles By Sydney

November 15, 2024
Healthcare Co. PACS Made False Claims Before IPO, Suit Says
November 13, 2024
Biotech Brass Misled Investors About Cancer Drugs, Suit Says
October 29, 2024
Y-mAbs Therapeutics Investors Get Final OK For $19.7M Deal
October 29, 2024
Biopharma Co. Escapes Investor Suit Over Drug Approval Lies
October 17, 2024
Acadia Hid Wrongful Detainment Of Patients, Investor Claims
September 25, 2024
Feds Urge Judge Not To Ax Novel Insider Trading Conviction
September 24, 2024
Philips Must Face Investor Suit Over FDA Compliance Issues
July 18, 2024
Ocugen Execs Hit With Derivative Suit Over Shoddy Controls
July 15, 2024
Walgreens Investor Sues Over Challenged Pharmacy Division
July 10, 2024
Skin Care Tech Co. Says Suit Shows 'Rough' Year, Not Fraud